REG - Avacta Group PLC - Appointment of Zeus Capital as Joint Broker

AvactaAnnouncement

Mon 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd0314Pa&default-theme=true

RNS Number : 0314P  Avacta Group PLC  30 June 2025

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Appointment of Zeus Capital as Joint Broker to Avacta Group plc

 

LONDON and PHILADELPHIA - June 30, 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing innovative, targeted oncology drugs, today
announces

the appointment of Zeus Capital as a joint broker to the Company with
immediate effect.

 

Peel Hunt and Panmure Liberum both continue in their respective roles as NOMAD
and Joint Broker and Joint Broker to the Company.

 

Related Party Transaction

 

Richard Hughes, a Director of the Company, is an associate of Zeus Capital as
defined under the AIM Rules.  Zeus Capital is therefore a related party of
the Company pursuant to the AIM Rules and the appointment of Zeus Capital
including a £75,000 annual retainer due to Zeus Capital is a related party
transaction.  The Directors (other than Richard Hughes who is an associate of
Zeus Capital) consider, having consulted with the Company's nominated
adviser Peel Hunt, that the appointment of Zeus Capital including the annual
retainer are fair and reasonable insofar as Shareholders are concerned.

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)

 James Steel / Chris Golden                                 www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)

 Emma Earl / Will Goode / Mark Rogers                       https://panmureliberum.com/

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

 

About Avacta - www.avacta.com (http://www.avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEADKEDLSSEFA